Shionogi & Co., Ltd.

4507

JP3347200002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 01:30:00 2026-02-12 am EST			5-day change	1st Jan Change
3,535.00 ^JPY	+1.17%		+3.12%	+24.43%

Jan. 30	Shionogi & Co.'s Nine-Month Profit Jumps 18%	MT
Jan. 29	Shionogi & Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI

Shionogi & Co Invests $2.13 Billion to Replace Pfizer as ViiV Healthcare Shareholder

Published on 01/20/2026 at 04:58 am EST

MT Newswires

Latest news about Shionogi & Co., Ltd.

Jan. 30	Shionogi & Co.'s Nine-Month Profit Jumps 18%	MT
Jan. 29	Shionogi & Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
Jan. 20	European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1%	MT
Jan. 20	GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update	DJ
Jan. 20	Shionogi & Co Invests $2.13 Billion to Replace Pfizer as ViiV Healthcare Shareholder	MT
Jan. 20	Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake	RE
Jan. 20	GSK Partner Shionogi to Acquire Pfizer's Stake in HIV-Focused ViiV Healthcare for $2.13 Billion	MT
Jan. 20	GSK, Shionogi Finalize Deal for Pfizer's Exit from ViiV Healthcare	MT
Jan. 20	GSK, Pfizer, and Shionogi agree on ViiV Healthcare shareholding changes	RE
Jan. 20	Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits	RE
Jan. 20	GSK makes $2.2 billion swoop for RAPT Therapeutics' food allergy drug	RE
Jan. 20	UK Stocks-Factors to watch on January 20	RE
Jan. 19	ViiV Healthcare Limited announced that it expects to receive $2.125 billion in funding from Shionogi & Co., Ltd.	CI
Jan. 19	Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1 Billion	DJ
Jan. 19	Shionogi & Co Ltd to acquire 11.7% voting rights in VIIV HEALTHCARE from GSK and Pfizer	RE
Jan. 15	Jefferies Adjusts Shionogi's Price Target to 3,100 Yen From 2,500 Yen, Keeps at Hold	MT
Jan. 08	Shionogi China receives approval from National Medical Products Administration for cefiderocol for treatment of complicated urinary tract infections	RE
Dec. 22	Shionogi & Co Ltd - Planned acquisition of global rights to Tanabe Pharma's Radicava ORS and IV Radic	RE
Dec. 22	Shionogi Wins Japan Approval for ZURZUVAE to Treat Depression	MT
Dec. 22	Shionogi & Co Ltd receive approval in Japan to manufacture and market Zurzuvae capsules 30 mg for treatment of major depressive disorder	RE
Dec. 10	Fed Outlook, Catalyst Dearth Cap Asian Stock Markets	MT
Dec. 09	Japan's Topix index touches record high in tentative trade before Fed, BOJ	RE
Dec. 01	Shionogi & Co Completes Acquisition of Japan Tobacco's Pharma Business	MT
Dec. 01	Japan Tobacco Completes Pharmaceutical Business Transfer to Shionogi	MT
Nov. 30	Shionogi & Co., Ltd. completed the acquisition of Pharmaceutical business of Japan Tobacco Inc from Japan Tobacco Inc..	CI

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

Employees

4,955

Sector

Pharmaceuticals

Calendar

Mar. 29 - Final dividend

More about the company